Interferon Alpha-2: Pre-Clinical and Clinical Evaluation: Proceedings of the Symposium held in Adjunction with the Second International Conference on Malignant Lymphoma, Lugano, Switzerland, June 13, 1984 / Edition 1

Interferon Alpha-2: Pre-Clinical and Clinical Evaluation: Proceedings of the Symposium held in Adjunction with the Second International Conference on Malignant Lymphoma, Lugano, Switzerland, June 13, 1984 / Edition 1

by Daniel L. Kisner
ISBN-10:
0898387019
ISBN-13:
9780898387018
Pub. Date:
04/30/1985
Publisher:
Springer US
ISBN-10:
0898387019
ISBN-13:
9780898387018
Pub. Date:
04/30/1985
Publisher:
Springer US
Interferon Alpha-2: Pre-Clinical and Clinical Evaluation: Proceedings of the Symposium held in Adjunction with the Second International Conference on Malignant Lymphoma, Lugano, Switzerland, June 13, 1984 / Edition 1

Interferon Alpha-2: Pre-Clinical and Clinical Evaluation: Proceedings of the Symposium held in Adjunction with the Second International Conference on Malignant Lymphoma, Lugano, Switzerland, June 13, 1984 / Edition 1

by Daniel L. Kisner

Hardcover

$131.24
Current price is , Original price is $149.99. You
$131.24  $149.99 Save 13% Current price is $131.24, Original price is $149.99. You Save 13%.
  • SHIP THIS ITEM
    Temporarily Out of Stock Online
  • PICK UP IN STORE

    Your local store may have stock of this item.

Product Details

ISBN-13: 9780898387018
Publisher: Springer US
Publication date: 04/30/1985
Series: Developments in Oncology , #27
Edition description: 1985
Pages: 112
Product dimensions: 6.10(w) x 9.25(h) x (d)

Table of Contents

1. Recombinant DNA Technology and Characterization of Recombinant Alpha-2 Interferon.- 2. Summary of Pre-Clinical Data.- 3. Synergy In Vitro and in Clinical Trials.- 4. Discussion: Pre-Clinical Panel.- 5. Phase I/II Clinical Trials.- 6. Phase II Evaluation in Patients with Non-Hodgkin’s Lymphoma. The Old World Experience. An Interim Report.- 7. High and Low Dose Treatment for High and Low Grade Non-Hodgkin’s Lymphoma.- 8. Use in Patients with Resistant and Relapsing Multiple Myeloma. A Phase II Study.- 9. Use in Hairy Cell Leukemia. An Update.- 10. Clinical Trials in Non-Hematologic Malignancies.- 11. Discussion: Clinical Panel.- 12. Conclusion.

From the B&N Reads Blog

Customer Reviews